X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/26/2852273/0/en/Ayala-Pharmaceuticals-Announces-Completion-of-Sale-of-AL102-to-Immunome.html
https://www.globenewswire.com//news-release/2024/02/20/2831772/0/en/Ayala-Pharmaceuticals-Announces-Completion-of-Enrollment-in-Phase-3-RINGSIDE-Study-Evaluating-AL102-in-Desmoid-Tumors.html
https://www.fiercebiotech.com/biotech/immunome-pays-50m-phase-3-desmoid-tumor-drug-playing-catchup-springworks
https://www.globenewswire.com//news-release/2024/02/06/2824285/0/en/Immunome-To-Acquire-AL102-A-Phase-3-Asset-for-the-Treatment-of-Desmoid-Tumors-From-Ayala-Pharmaceuticals.html
https://www.globenewswire.com//news-release/2023/11/06/2774068/0/en/Ayala-Pharmaceuticals-Announces-AL102-Receives-Orphan-Drug-Designation-for-Desmoid-Tumors.html
https://www.globenewswire.com//news-release/2023/11/06/2774078/0/en/GigaGen-Presents-IND-Enabling-Data-and-Phase-1-Trial-Strategy-for-its-Novel-Anti-CTLA-4-Oncology-Drug-Candidate-GIGA-564-at-SITC-2023.html
https://www.globenewswire.com//news-release/2023/10/23/2764574/0/en/Ayala-Pharmaceuticals-Presents-Updated-AL102-Results-from-Phase-2-Clinical-Trial-in-Desmoid-Tumors-at-ESMO-Congress-2023.html
https://www.globenewswire.com//news-release/2023/10/19/2763148/0/en/Ayala-Pharmaceuticals-Announces-Closing-of-Merger-with-Biosight.html
https://www.globenewswire.com/news-release/2023/08/10/2723211/0/en/Ayala-Pharmaceuticals-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
Market Place
Share 
